Navigation Links
Compounds outsmart solid tumors' malfunctioning machinery
Date:7/17/2013

SAN ANTONIO (July 17, 2013) Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting effects.

This machinery, the proteasome, is deregulated in cancer. Agents called protease inhibitors are viewed as potential anti-cancer therapies, but they indiscriminately curb proteasome activity, which also includes protein recycling. Such strategy is effective to kill cells in aggressive blood cancers but leads to drug resistance and excessive toxicity in solid tumors.

Fine-tuning

The new strategy may change that. By basically outsmarting the cell's machinery, compounds called allosteric regulators are able to fine-tune the proteasome actions instead of block them. "The result is that cell lines from solid tumors, which are resistant to existing therapy, are sensitive to these agents," said Pawel Osmulski, Ph.D., assistant professor of molecular medicine at the Health Science Center. He and Maria Gaczynska, Ph.D., associate professor of molecular medicine, co-authored a report in Molecular Pharmacology that provides a basis for this approach.

'Highly beneficial'

Deregulation of the proteasome's actions is noted in cancer or during aging and contributes to intracellular pathologies. "It is easy to envision that precise adjusting of the proteasome activities with therapeutic molecules would be highly beneficial in many human conditions," Dr. Osmulski said.

Inhibition and activation

"Allosteric regulators are better than proteasome-affecting agents used in clinics because they do not induce classical drug resistance," Dr. Gaczynska said. "They bind to sites on the proteasome molecule used by natural regulatory proteins. They are more specific and are not restricted to proteasome inhibition but can activate the proteasome under certain conditions."

The new strategy was serendipitously found during experiments with rapamycin, a drug that in a highly publicized study by the UT Health Science Center's Barshop Institute for Longevity and Aging Studies was found to extend life span in mice.

Potential

The Molecular Pharmacology report and follow-up studies describe the unexpected and highly desired effects that rapamycin and similar compounds elicit on the proteasome. Based on these studies, it would be possible to design a new line of proteasome regulators with anti-cancer properties, Drs. Osmulski and Gaczynska said. This work is in progress in their laboratory. Drs. Osmulski and Gaczynska are affiliated with the Barshop Institute and with the Cancer Therapy & Research Center at The University of Texas Health Science Center San Antonio.


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related medicine news :

1. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
2. Compounds activate key cancer enzyme to interfere with tumor formation
3. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
4. Dirty Drugs and We Know It: Attorneys at Console & Hollawell Comment on ISMP Survey Relating to Contaminated Drug Compounds and the Risks to Consumers
5. Advance in re-engineering photosynthesis to make drugs, compounds or ingredients
6. NIH-supported researchers identify new class of malaria compounds
7. Ginger compounds may be effective in treating asthma symptoms
8. Many solid tumors carry genetic changes targeted by existing compounds
9. Some Whooping Cough Strains Now Outsmarting Vaccine
10. AvePoint Outsmarts the Chaos with Interactive Meetings App for Microsoft SharePoint 2013
11. OHSU research highlights promising strategy to help vaccines outsmart HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 2016 , ... 'Tis the season for family, festivity, food and fun! Temptation ... season when eating healthy, staying active, and taking medication and doing daily foot health ... , "Shopping trips, parties and family gatherings can take their toll on our ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... , ... December 06, 2016 , ... "Add realistic flares ... flicker, flash, and flare from clip to clip with high quality 4K lens flare ... 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the leader ... manufacturing data that support SB-525, its gene therapy program for ... the American Society of Hematology (ASH) being held in ... "We have developed an improved gene therapy vector ... competitive, and we remain on track to file an Investigational ...
Breaking Medicine Technology: